

Neuberg Diagnostics to invest upto Rs 150 crore for expansion in North & East

16 December 2020 | News

Dr Amrita Singh, an experienced industry expert, has been appointed as Chief of Lab Services for the region.



Chennai based Neuberg Diagnostics has announced its expansion plans in Delhi and Kolkata in Q4FY21. Dr Amrita Singh, an experienced industry expert, has been appointed as Chief of Lab Services for the region. She will be overseeing the company's expansion and technical operations in North and East India. For expansion in these two regions, the company plans to invest upto Rs 150 crore for organic and inorganic business growth.

The company aims to add another 10 labs in the next quarter and 30 labs by end of next fiscal. It also plans to commence commercial operations in the US in next quarter.

Dr GSK Velu, Chairman and Managing Director, Neuberg Diagnostics said, "With a commitment to provide affordable diagnostics, we are now rolling out our quality routine and referral lab testing services in North & East India. Additionally, we are aiming to launch new generation techniques that are deployed for diagnosing complicated diseases where deeper analysis is required.

"South and West have been our focus markets over the past three years. We are already leaders in markets like Karnataka, Gujarat, Tamil Nadu, Kerala and South Maharashtra, and are expanding our presence in other key markets like Andhra Pradesh & Telangana and Mumbai in Maharashtra by next quarter. Now we want to be a significant player in North and East. In both the regions, we are looking for organic and inorganic growth catering to the testing needs," added Dr Velu.

A Ganesan, Vice Chairman, Neuberg Diagnostics said, "Currently, through hospital lab management and customer walk-in centres, we already have a presence in Delhi NCR and Chandigarh. Bringing on board Dr Amrita Singh and a senior leadership team based in Delhi and Kolkata will provide the necessary management bandwidth and technical expertise to grow our operations in North and East India over the next two years. Our northern growth will be similar to South and West India, which has enabled us to become one of the top 4 diagnostics path lab players within 3 years of our operations, since Oct 2017."